FDA User Fee Bills: Is It Possible For Reauthorization To Be Too Clean?
Executive Summary
First draft of user fee omnibus bill is about as 'clean' as a bill can be – free of the policy riders that have always been attached to US FDA funding legislation in past cycles. That is good news for industry, which is eager to see the program reauthorized with as little drama as possible, but could the bill actually be too clean?
You may also be interested in...
Rhetoric Meets Reality: A Timeline Of Trump's First 100 Days
President Trump is empty-handed on health care victories so far, as initial health reform repeal efforts collapsed and the shock value of drug pricing tweets wore off. But some actions may evolve into biopharma impact further down the road.
First Draft FDA User Fee Bill Is Squeaky Clean
House and Senate release discussion draft of user fee reauthorization legislation that does not include any additional policy or practice changes for US FDA, though they may arrive later.
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.